Olaparib in the management of ovarian cancer
Alterations in the homologous repair pathway are thought to occur in 30%–50% of epithelial ovarian cancers. Cells deficient in homologous recombination rely on alternative pathways for DNA repair in order to survive, thereby providing a potential target for therapy. Olaparib, a poly(ADP-ribose) poly...
Main Authors: | Bixel, Kristin, Hays, John L |
---|---|
Format: | Online |
Language: | English |
Published: |
Dove Medical Press
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538690/ |
Similar Items
-
Profile of olaparib in the treatment of advanced ovarian cancer
by: Chase, Dana M, et al.
Published: (2016) -
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
by: Shaw, Heather M, et al.
Published: (2013) -
OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01) -
Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
by: Bangham, Madeleine, et al.
Published: (2016) -
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
by: Whicker, Margaret E., et al.
Published: (2016)